| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Immune activation (NK cells / macrophages) |
NK activity ↑; macrophage activation ↑ (reported) |
Immune surveillance support |
R, G |
Immunostimulatory |
One of the most consistent themes; fucoidan enhances innate immune responses in tumor-bearing animal models. |
| 2 |
NF-κB inflammatory / survival signaling |
NF-κB ↓; cytokines ↓ (reported) |
Inflammatory tone modulation |
R, G |
Anti-inflammatory / anti-survival |
Suppression of NF-κB contributes to reduced tumor-promoting inflammation and survival signaling. |
| 3 |
PI3K → AKT signaling |
PI3K/AKT ↓; proliferation ↓ (model-dependent) |
↔ |
R, G |
Growth signaling suppression |
Reported in multiple cancer cell models; often secondary to upstream immune or redox modulation. |
| 4 |
Intrinsic apoptosis (mitochondrial pathway) |
Caspases ↑; Bax ↑; Bcl-2 ↓ (reported) |
Minimal apoptosis in normal cells (dose-dependent) |
G |
Apoptotic induction |
Apoptosis frequently reported in vitro; magnitude depends on molecular weight and sulfation. |
| 5 |
Angiogenesis (VEGF signaling) |
VEGF ↓; angiogenesis ↓ (reported) |
↔ |
G |
Anti-angiogenic |
Anti-angiogenic activity is one of the more reproducible findings in preclinical systems. |
| 6 |
Metastasis / adhesion (selectins, ECM interaction) |
Tumor adhesion ↓; invasion ↓ (reported) |
↔ |
G |
Anti-metastatic |
Sulfated structure may interfere with selectin-mediated adhesion and tumor cell migration. |
| 7 |
ROS / redox modulation |
ROS modulation (context-dependent) |
Antioxidant protection reported |
P, R |
Redox modulation (secondary) |
Fucoidan is not a primary pro-oxidant; redox effects appear secondary to signaling changes. |
| 8 |
Chemo / radiation synergy |
Sensitization ↑ (reported in models) |
↔ |
G |
Adjunct potential |
May enhance cytotoxic therapy response; evidence largely preclinical. |
| 9 |
Warburg metabolism |
Indirect modulation (not a primary glycolysis inhibitor) |
↔ |
R |
Metabolic secondary effect |
Metabolic changes likely downstream of survival pathway suppression rather than direct glycolysis blockade. |
| 10 |
Bioavailability / heterogeneity constraint |
Effects vary by molecular weight and source |
Generally well tolerated orally |
— |
Translation constraint |
Composition varies widely by seaweed species and extraction method; standardization is critical. |